CRANBURY, N.J. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has

CRANBURY, N.J. , Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has

CRANBURY, N.J. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has

Topline results from the NORSE 1 study of ONS-5010 expected to be announced in the third quarter of calendar 2020 Enrollment in the NORSE 2 study underway SPA agreement reached with FDA for NORSE 4, 5 and 6 studies CRANBURY, N.J. , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

ONS-5010, an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two clinical trials to treat wet age-related macular degeneration (wet AMD – NORSE 1 and 2).   SPAs for clinical trial protocols for NORSE 4 for branch retinal vein occlusion (“BRVO”) and

CRANBURY, N.J. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the Ladenburg Thalmann 2019 Healthcare Conference being held at the Sofitel New York in New York on September 24 th .

CRANBURY, N.J. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the H.C. Wainwright 21st Annual Healthcare Conference that is being held at the Lotte New York Palace Hotel in New York on September 9

Initial data expected to be announced in calendar Q3 2020 CRANBURY, N.J. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the

CRANBURY, N.J. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) today reported business highlights and financial results for its third quarter ended June 30, 2019 . Recent Highlights: NORSE 2 (formerly “ONS-5010-002”) Phase 3 clinical trial begins dosing

Full enrollment expected to occur in calendar Q4 2019 CRANBURY, N.J. , July 16, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate